Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 18/20 | 0.56 |
| ▸ | PDE2A | O00408 | 1/20 | 0.51 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.51 |
| ▸ | GALR3 | O60755 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9781549 | 0.88 | GPR119 (0.55) | GPR119PDE2APDE3BPDE3AGALR3 | |
| SCHEMBL9686555 | 0.84 | GPR119 (0.60) | GPR119PDE2APDE3BPDE3A | |
| SCHEMBL2583128 | 0.83 | GALR3 (0.66) | PDE3BPDE3AGALR3MAPTTHRB | |
| SCHEMBL6934765 | 0.83 | GPR119 (0.61) | GPR119PDE2APDE3BPDE3A | |
| SCHEMBL9686622 | 0.82 | GPR119 (0.56) | GPR119PDE2APDE3BPDE3A | |
| SCHEMBL9686762 | 0.81 | GPR119 (0.66) | GPR119PDE2APDE3BPDE3A | |
| SCHEMBL7352543 | 0.81 | MAPT (0.73) | GPR119PDE2APDE3BPDE3AGALR3 | |
| SCHEMBL7340003 | 0.77 | GPR119 (0.53) | GPR119PDE2APDE3BPDE3A | |
| SCHEMBL9686758 | 0.77 | PDE2A (0.62) | GPR119PDE2APDE3BPDE3A | |
| SCHEMBL9686551 | 0.77 | GPR119 (0.56) | GPR119PDE2APDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2566864-B1 | PYRIDAZINONES AS GPR119 AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2014-09-03 | — | — | EP | disclosed |
| US-8772323-B2 | Benzoxazole- and tetrahydrobenzoxazole-substituted pyridazinones as GPR119 agonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-08 | — | — | US | disclosed |
| US-20130172323-A1 | PYRIDAZINONES AS GPR119 AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-04 | — | — | US | disclosed |
| EP-2566864-A2 | PYRIDAZINONES AS GPR119 AGONISTS | Boehringer Ingelheim International GmbH (DE) | 2013-03-13 | — | — | EP | disclosed |
| WO-2011138427-A2 | PYRIDAZINONES AS GPR119 AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172323-A1 | PYRIDAZINONES AS GPR119 AGONISTS | GPR65, GPR119, GPR55 | GPR119 2/4885PDE2A 1099/4885PDE3B 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.